Becton, Dickinson and Company
BDX · NYSE
$182.92+$21.6213.84%
$182.90-$0.020.01%
BDX · NYSE
BDX is a medical-technology company that sells products used in healthcare delivery, generating revenue from those product sales. The supplied material does not identify its operating segments, product categories, customer mix, or the approximate share contributed by each segment, so a segment-by-segment revenue breakdown cannot be supported here. At the reported FY2025 scale, BDX generated $21.8 billion of revenue and $1.7 billion of net income, versus $20.2 billion and $1.7 billion, respectively, in FY2024. The company is also being evaluated ahead of its quarter ended June 2026.
BDX rose $3.78, or 2.27%, over the supplied week, from $166.34 on July 28 to $170.12 on August 4. Trading was volatile rather than steadily higher: shares gained $2.06 on July 29, surrendered $2.95 on July 30, and were essentially flat July 31 before jumping $4.59 on August 3 and edging down $0.09 the next day. The evidence does not identify a company-specific announcement, earnings release, guidance change, contract, or analyst action that explains the move. The only BDX-specific item supplied was a Zacks preview of the quarter ended June 2026, which discusses estimates and operating metrics but reports no results or new guidance. Accordingly, the week’s catalyst is unresolved from the supplied information.
